Literature DB >> 22795541

Safeguarding pluripotent stem cells for cell therapy with a non-viral, non-integrating episomal suicide construct.

Qingguo Zhao1, Baisong Lu, Sunil K George, James J Yoo, Anthony Atala.   

Abstract

Pluripotent stem cells provide an unlimited cell source for cell therapy. However, residual pluripotent stem cells after differentiation can form tumors. Modifying stem cells with suicide constructs through integrating plasmid DNA and viral vectors has been attempted to specifically eliminate residual pluripotent stem cells after differentiation. However, integration of foreign DNA has the potential of insertional mutagenesis, position effects and silencing. Scaffold/matrix attachment region (S/MAR)-based plasmid DNA can be maintained extra-chromosomally, offering a safer alternative to integrating vectors for this purpose. Here, we report the design of an S/MAR-based suicide construct capable of episomal maintenance and specifically killing pluripotent stem cells but not differentiated cells in the presence of ganciclovir. Treating cells differentiated from episomal suicide construct-modified stem cells with ganciclovir reduces the tumor formation risk after cell transplantation. Tumors formed by such modified pluripotent stem cells could be inhibited by ganciclovir administration. This episomal suicide construct enables negative selection of residual pluripotent stem cells in vitro and control of tumors formed from residual pluripotent stem cells in vivo.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795541     DOI: 10.1016/j.biomaterials.2012.06.038

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  4 in total

1.  Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives.

Authors:  Go Itakura; Soya Kawabata; Miki Ando; Yuichiro Nishiyama; Keiko Sugai; Masahiro Ozaki; Tsuyoshi Iida; Toshiki Ookubo; Kota Kojima; Rei Kashiwagi; Kaori Yasutake; Hiromitsu Nakauchi; Hiroyuki Miyoshi; Narihito Nagoshi; Jun Kohyama; Akio Iwanami; Morio Matsumoto; Masaya Nakamura; Hideyuki Okano
Journal:  Stem Cell Reports       Date:  2017-03-02       Impact factor: 7.765

Review 2.  Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges.

Authors:  Elizabeth Ford; Jodie Pearlman; Travis Ruan; John Manion; Matthew Waller; Gregory G Neely; Leslie Caron
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

3.  Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy.

Authors:  Hiroaki Mashima; Rong Zhang; Tsuyoshi Kobayashi; Hirotake Tsukamoto; Tianyi Liu; Tatsuaki Iwama; Yuichiro Hagiya; Masateru Yamamoto; Satoshi Fukushima; Seiji Okada; Alimjan Idiris; Shin Kaneko; Tetsuya Nakatsura; Hideki Ohdan; Yasushi Uemura
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-05       Impact factor: 6.698

4.  Selective Ablation of Tumorigenic Cells Following Human Induced Pluripotent Stem Cell-Derived Neural Stem/Progenitor Cell Transplantation in Spinal Cord Injury.

Authors:  Kota Kojima; Hiroyuki Miyoshi; Narihito Nagoshi; Jun Kohyama; Go Itakura; Soya Kawabata; Masahiro Ozaki; Tsuyoshi Iida; Keiko Sugai; Shuhei Ito; Ryuji Fukuzawa; Kaori Yasutake; Francois Renault-Mihara; Shinsuke Shibata; Morio Matsumoto; Masaya Nakamura; Hideyuki Okano
Journal:  Stem Cells Transl Med       Date:  2018-11-28       Impact factor: 6.940

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.